相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Orlistat-associated adverse effects and drug interactions - A critical review
Theodosios D. Filippatos et al.
DRUG SAFETY (2008)
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2
Vasilios G. Saougos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin
Irene F. Gazi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
D. P. Mikhailidis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
T. D. Filippatos et al.
ATHEROSCLEROSIS (2007)
Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials
Mary Ellen Sweeney et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Zetia: Inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia
Harry R. Davis et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2007)
Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease
Samir Parekh et al.
GASTROENTEROLOGY (2007)
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia
Mihalis Kalogirou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk - The Framingham Heart Study
Douglas S. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis
Nimer Assy et al.
GUT (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview
Irene F. Gazi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
NPC1L1: Evolution from pharmacological target to physiological sterol transporter
Murray W. Huff et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients
Manuel Gonzalez-Ortiz et al.
CARDIOVASCULAR DRUGS AND THERAPY (2006)
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
JD Otvos et al.
CIRCULATION (2006)
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
SS Daskalopoulou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma
I Gazi et al.
CLINICAL CHEMISTRY (2005)
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
TD Filippatos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors
DJ Kim et al.
DIABETIC MEDICINE (2005)
Influence of α-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype
P Wilkinson et al.
ATHEROSCLEROSIS (2005)
Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men -: 13-year follow-up data from the Quebec Cardiovascular Study
AC St-Pierre et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Evaluation of methods for the measurement of low-density lipoprotein cholesterol
ET Bairaktari et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2005)
A review of the metabolic effects of sibutramine
TD Filippatos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study
HHS Oei et al.
CIRCULATION (2005)
The effects of orlistat on metabolic parameters and other cardiovascular risk factors
DN Kiortsis et al.
DIABETES & METABOLISM (2005)
Pathogenesis and treatment of kidney disease and hypertension - Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
VG Athyros et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
CIRCULATION (2004)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
CM Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
XENical in the prevention of diabetes in obese subjects (XENDOS) study
JS Torgerson et al.
DIABETES CARE (2004)
Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia
CP Lucas et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
AD Tselepis et al.
ATHEROSCLEROSIS SUPPLEMENTS (2002)
Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension
AM Sharma et al.
JOURNAL OF HYPERTENSION (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study
E Muls et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program
A Sartorio et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2001)
Orlistat inhibits dietary cholesterol absorption
B Mittendorfer et al.
OBESITY RESEARCH (2001)
分享论文
